Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the objective tumor response rate of amrubicin when
administered as second-line therapy to ED-SCLC patients who have refractory or progressive
disease.